SG11201908023YA - T cell receptors and immune therapy using the same against prame positive cancers - Google Patents
T cell receptors and immune therapy using the same against prame positive cancersInfo
- Publication number
- SG11201908023YA SG11201908023YA SG11201908023YA SG11201908023YA SG 11201908023Y A SG11201908023Y A SG 11201908023YA SG 11201908023Y A SG11201908023Y A SG 11201908023YA SG 11201908023Y A SG11201908023Y A SG 11201908023YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- tuebingen
- march
- pct
- taa
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 101001095088 Homo sapiens Melanoma antigen preferentially expressed in tumors Proteins 0.000 abstract 3
- 102100037020 Melanoma antigen preferentially expressed in tumors Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464489—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT olioloiollm onolom n °noun (10) International Publication Number WO 2018/172533 A2 (51) International Patent Classification: A61K 39/395 (2006.01) (21) International Application Number: PCT/EP2018/057482 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10 2017 106 305.6 23 March 2017 (23.03.2017) DE 62/475,329 23 March 2017 (23.03.2017) US (71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH [DE/DE]; Paul-Ehrlich-Strasse 15, 72076 Tuebingen (DE). (72) Inventors: ALTEN, Leonie; Weissdornweg 14, App. 161, 72076 Tuebingen (DE). MAURER, Dominik; Fleinerweg 7, 72116 Moessingen (DE). BUNK, Sebastian; Gertrud- Baeumer-Str. 19/1, 72074 Tuebingen (DE). WAGNER, Claudia; Nuertinger Strasse 32, 72074 Tuebingen (DE). FERBER, Mathias; 1 Rue de Paradis, 75010 Paris (FR). (74) Agent: BOEHMERT & BOEHMERT; Jan B. KRAUSS, PettenkoferstraBe 22, 80336 Mfinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) with sequence listing part of description (Rule 5.2(a)) (54) Title: T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST PRAME POSITIVE CANCERS (57) : The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762475329P | 2017-03-23 | 2017-03-23 | |
DE102017106305.6A DE102017106305A1 (en) | 2017-03-23 | 2017-03-23 | New T cell receptors and their use in immunotherapies against prame-positive cancers |
PCT/EP2018/057482 WO2018172533A2 (en) | 2017-03-23 | 2018-03-23 | T cell receptors and immune therapy using the same against prame positive cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908023YA true SG11201908023YA (en) | 2019-10-30 |
Family
ID=61899213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908023Y SG11201908023YA (en) | 2017-03-23 | 2018-03-23 | T cell receptors and immune therapy using the same against prame positive cancers |
Country Status (17)
Country | Link |
---|---|
US (2) | US11236145B2 (en) |
EP (1) | EP3600409A2 (en) |
JP (2) | JP2020511152A (en) |
KR (1) | KR20190132655A (en) |
CN (1) | CN110494160A (en) |
AU (1) | AU2018240501A1 (en) |
BR (1) | BR112019019523A2 (en) |
CA (1) | CA3056493A1 (en) |
CL (1) | CL2019002645A1 (en) |
CO (1) | CO2019011688A2 (en) |
CR (1) | CR20190482A (en) |
IL (2) | IL310552A (en) |
MX (2) | MX2019011260A (en) |
PE (1) | PE20191493A1 (en) |
PH (1) | PH12019502151A1 (en) |
SG (1) | SG11201908023YA (en) |
TW (1) | TWI799922B (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
JP2022521513A (en) | 2019-02-20 | 2022-04-08 | フレッド ハッチンソン キャンサー リサーチ センター | RAS neoantigen-specific binding proteins and their use |
DE102019108125B4 (en) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | CD28 T-CELL CULTURES, COMPOSITIONS AND METHODS OF USE |
WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
EP3965818A4 (en) * | 2019-05-08 | 2023-05-31 | Janssen Biotech, Inc. | Materials and methods for modulating t cell mediated immunity |
JP2022534716A (en) | 2019-05-27 | 2022-08-03 | イマティクス ユーエス,アイエヌシー. | Viral vectors and their use in adoptive cell therapy |
JP2023515131A (en) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス,アイエヌシー. | Methods of expanding T cells for the treatment of cancer and related malignancies |
DE102020111571A1 (en) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES |
WO2022017435A1 (en) * | 2020-07-22 | 2022-01-27 | 信达生物制药(苏州)有限公司 | SERIES OF BIOMARKERS OF CONSENSUS SEQUENCES IN CDR3 SEQUENCE OF TCR-β CHAIN AND APPLICATION THEREOF |
TW202227616A (en) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | Methods for isolating cd8+ selected t cells |
EP4271481A2 (en) | 2020-12-31 | 2023-11-08 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
AU2022270361A1 (en) | 2021-05-05 | 2023-11-16 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
WO2023288267A1 (en) | 2021-07-14 | 2023-01-19 | 2Seventy Bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
US20230190805A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Methods of identifying metastatic lesions in a patient and treating thereof |
CN113789304B (en) * | 2021-10-14 | 2023-03-31 | 深圳大学总医院 | High affinity TCR and uses thereof |
CN113817044B (en) * | 2021-10-14 | 2023-10-13 | 深圳大学总医院 | T cell receptor, related engineering cell and application thereof |
US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
WO2023196997A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
CN115073584B (en) * | 2022-05-07 | 2023-10-20 | 溧阳瑅赛生物医药有限公司 | TCR capable of specifically recognizing PRAME antigen peptide and application thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107238706A (en) | 2011-06-28 | 2017-10-10 | 株式会社癌免疫研究所 | The acceptor gene of peptide cancer antigen-specific t cell |
RU2578009C2 (en) | 2013-05-08 | 2016-03-20 | Закрытое акционерное общество "ЕВРОГЕН" | Method for identifying native pairs of dna or rna fragments in same living cells |
JP7113618B2 (en) | 2014-07-15 | 2022-08-05 | ジュノー セラピューティクス インコーポレイテッド | Engineered cells for adoptive cell therapy |
CA2978171A1 (en) | 2015-03-10 | 2016-09-15 | J.H. Frederik Falkenburg | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof |
EP3067366A1 (en) | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
WO2016191246A2 (en) | 2015-05-22 | 2016-12-01 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for a prame peptide |
CN106084036A (en) | 2015-11-02 | 2016-11-09 | 广州市香雪制药股份有限公司 | Identify the φt cell receptor of DAGE small peptide |
CN106478809B (en) | 2015-11-06 | 2018-06-01 | 广东香雪精准医疗技术有限公司 | Identify the TCR of PRAME antigen small peptide |
CN106519019B (en) | 2015-11-06 | 2018-07-03 | 广东香雪精准医疗技术有限公司 | Identify the TCR of PRAME antigen |
CN106831978B (en) | 2015-12-04 | 2020-05-26 | 中国科学院广州生物医药与健康研究院 | T cell receptor recognizing PRAME antigen |
CN106699874B (en) | 2016-03-29 | 2018-06-05 | 广东香雪精准医疗技术有限公司 | Identify the T cell receptor of PRAME antigen small peptide |
US11732020B2 (en) | 2016-06-17 | 2023-08-22 | Medigene Immunotherapies Gmbh | T cell receptors and uses thereof |
DE102017106305A1 (en) * | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | New T cell receptors and their use in immunotherapies against prame-positive cancers |
-
2018
- 2018-03-22 US US15/928,785 patent/US11236145B2/en active Active
- 2018-03-23 BR BR112019019523A patent/BR112019019523A2/en unknown
- 2018-03-23 EP EP18715559.3A patent/EP3600409A2/en active Pending
- 2018-03-23 MX MX2019011260A patent/MX2019011260A/en unknown
- 2018-03-23 TW TW110126772A patent/TWI799922B/en active
- 2018-03-23 JP JP2019552175A patent/JP2020511152A/en active Pending
- 2018-03-23 KR KR1020197030006A patent/KR20190132655A/en not_active Application Discontinuation
- 2018-03-23 CN CN201880019206.5A patent/CN110494160A/en active Pending
- 2018-03-23 IL IL310552A patent/IL310552A/en unknown
- 2018-03-23 CA CA3056493A patent/CA3056493A1/en active Pending
- 2018-03-23 AU AU2018240501A patent/AU2018240501A1/en active Pending
- 2018-03-23 PE PE2019001902A patent/PE20191493A1/en unknown
- 2018-03-23 IL IL269578A patent/IL269578B1/en unknown
- 2018-03-23 CR CR20190482A patent/CR20190482A/en unknown
- 2018-03-23 SG SG11201908023Y patent/SG11201908023YA/en unknown
-
2019
- 2019-09-16 CL CL2019002645A patent/CL2019002645A1/en unknown
- 2019-09-19 PH PH12019502151A patent/PH12019502151A1/en unknown
- 2019-09-20 MX MX2023003463A patent/MX2023003463A/en unknown
- 2019-10-22 CO CONC2019/0011688A patent/CO2019011688A2/en unknown
-
2021
- 2021-12-16 US US17/553,017 patent/US20220098270A1/en active Pending
-
2023
- 2023-03-20 JP JP2023044130A patent/JP2023088973A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202208420A (en) | 2022-03-01 |
CA3056493A1 (en) | 2018-09-27 |
CR20190482A (en) | 2020-01-07 |
PH12019502151A1 (en) | 2020-06-29 |
US11236145B2 (en) | 2022-02-01 |
CL2019002645A1 (en) | 2019-12-13 |
MX2023003463A (en) | 2023-04-19 |
JP2023088973A (en) | 2023-06-27 |
AU2018240501A1 (en) | 2019-10-31 |
MX2019011260A (en) | 2019-12-05 |
IL269578A (en) | 2019-11-28 |
IL269578B1 (en) | 2024-03-01 |
KR20190132655A (en) | 2019-11-28 |
CO2019011688A2 (en) | 2020-02-28 |
JP2020511152A (en) | 2020-04-16 |
BR112019019523A2 (en) | 2020-04-22 |
IL310552A (en) | 2024-03-01 |
TWI799922B (en) | 2023-04-21 |
US20220098270A1 (en) | 2022-03-31 |
US20180273602A1 (en) | 2018-09-27 |
EP3600409A2 (en) | 2020-02-05 |
CN110494160A (en) | 2019-11-22 |
PE20191493A1 (en) | 2019-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908023YA (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
SG11201807590SA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
SG11201805268XA (en) | T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex | |
SG11201807868VA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201900468YA (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201806150RA (en) | Psma and cd3 bispecific t cell engaging antibody constructs | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201806951TA (en) | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | |
SG11201806261XA (en) | Bcma antibodies and use of same to treat cancer and immunological disorders | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201809041TA (en) | Compositions and methods for selective protein expression | |
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201805872SA (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
SG11201807300PA (en) | Uterine cancer treatments | |
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201906198PA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |